Literature DB >> 26688439

Identification of a recurrent frameshift mutation at the LDLR exon 14 (c.2027delG, p.(G676Afs*33)) causing familial hypercholesterolemia in Saudi Arab homozygous children.

Faisal A Al-Allaf1, Abdullah Alashwal2, Zainularifeen Abduljaleel3, Mohiuddin M Taher3, Shahid S Siddiqui4, Abdellatif Bouazzaoui3, Hala Abalkhail2, Rakan Aun5, Ahmad F Al-Allaf6, Iman AbuMansour5, Zohor Azhar5, Faisal A Ba-Hammam5, Wajahatullah Khan7, Mohammad Athar8.   

Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant disease, predominantly caused by variants in the low-density lipoprotein (LDL) receptor gene (LDLR). Herein, we describe genetic analysis of severely affected homozygous FH patients who were mostly resistant to statin therapy and were managed on an apheresis program. We identified a recurrent frameshift mutation p.(G676Afs*33) in exon 14 of the LDLR gene in 9 probands and their relatives in an apparently unrelated Saudi families. We also describe a three dimensional homology model of the LDL receptor protein (LDLR) structure and examine the consequence of the frameshift mutation p.(G676Afs*33), as this could affect the LDLR structure in a region involved in dimer formation, and protein stability. This finding of a recurrent mutation causing FH in the Saudi population could serve to develop a rapid genetic screening procedure for FH, and the 3D-structure analysis of the mutant LDLR, may provide tools to develop a mechanistic model of the LDLR function.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arab; Atherosclerosis; Cholesterol; Coronary heart diseases (CHD); Familial hypercholesterolemia (FH); Frameshift mutation; Genetics; Low-density lipoprotein receptor (LDLR); MD simulation; PCR; Protein structure; Saudi Arabia

Mesh:

Substances:

Year:  2015        PMID: 26688439     DOI: 10.1016/j.ygeno.2015.12.001

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  4 in total

Review 1.  The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry.

Authors:  Faisal Alallaf; Fatima Amanullah H Nazar; Majed Alnefaie; Adel Almaymuni; Omran Mohammed Rashidi; Khalid Alhabib; Fahad Alnouri; Mohamed-Nabil Alama; Mohammad Athar; Zuhier Awan
Journal:  Open Cardiovasc Med J       Date:  2017-07-26

Review 2.  Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting.

Authors:  Moeber Mahzari; Hawazen Zarif
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

3.  Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen.

Authors:  Zuhier Ahmed Awan; Omran M Rashidi; Bandar Ali Al-Shehri; Kaiser Jamil; Ramu Elango; Jumana Y Al-Aama; Robert A Hegele; Babajan Banaganapalli; Noor A Shaik
Journal:  Front Med (Lausanne)       Date:  2021-06-25

4.  Xanthomas Can Be Misdiagnosed and Mistreated in Homozygous Familial Hypercholesterolemia Patients: A Call for Increased Awareness Among Dermatologists and Health Care Practitioners.

Authors:  Fahad Alnouri; Faisal A Al-Allaf; Mohammad Athar; Zainularifeen Abduljaleel; Moheeb Alabdullah; Dalal Alammari; Menwar Alanazi; Fahmi Alkaf; Abeer Allehyani; Mohammad A Alotaiby; Abdullah Alshehri; Abdellatif Bouazzaoui; Hussam Karrar; Mohiuddin M Taher
Journal:  Glob Heart       Date:  2020-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.